CHRS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Coherus Oncology Inc (CHRS) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the company shows potential in its pipeline and has positive analyst ratings, the technical indicators are neutral, and there are no strong proprietary trading signals to suggest immediate action. Additionally, the company is still operating at a net loss, and the upcoming earnings report may provide more clarity on its financial trajectory. For now, it is better to hold and reassess after the earnings announcement.
The MACD is below 0 and negatively contracting, indicating a lack of bullish momentum. RSI is neutral at 59.499, and moving averages are converging, showing no clear trend. The stock is trading near its pivot level of 1.691, with resistance at 1.789 and support at 1.594. Overall, technical indicators suggest a neutral trend.
Analyst coverage initiated with an Outperform rating and a $10 price target, citing promising clinical developments.
Revenue growth of 91.19% YoY and gross margin improvement to 67.84% in Q3
Focus on growing sales of LOQTORZI® and advancing new indications.
The company is still operating at a net loss (-$35.53M in Q3 2025), despite improvements.
No significant insider or hedge fund trading activity to indicate confidence.
Neutral technical indicators with no clear upward momentum.
In Q3 2025, revenue increased by 91.19% YoY to $11.57M, and gross margin improved to 67.84%. However, the company remains unprofitable, with a net loss of -$35.53M and EPS of -0.31, albeit showing YoY improvement.
Oppenheimer initiated coverage with an Outperform rating and a $10 price target, citing promising clinical developments and high-potential early-stage opportunities in its pipeline.
